PMID- 28795354
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20190704
IS  - 1995-820X (Electronic)
IS  - 1674-0769 (Print)
IS  - 1995-820X (Linking)
VI  - 32
IP  - 4
DP  - 2017 Aug
TI  - Drug resistance mutation profiles of the drug-naive and first-line 
      regimen-treated HIV-1-infected population of Suzhou, China.
PG  - 271-279
LID - 10.1007/s12250-017-4002-y [doi]
AB  - Little is known about the prevalence of drug-resistant mutations in 
      HIV-1-positive individuals in Suzhou, China. To elucidate the transmitted drug 
      resistance (TDR) and acquired drug resistance mutation (ADR) profiles, we 
      collected blood specimens from 127 drug-naive and 117 first-line drug-treated 
      HIV-1-infected individuals sampled from 2014 to 2016 in Suzhou. We successfully 
      amplified pol fragments from 100 drug-naive and 20 drug-treated samples. We then 
      determined the drug-resistant mutations to protease (PR) and 
      reverse-transcriptase (RT) inhibitors according to the Stanford drug resistance 
      database. Overall, 11 and 13 individuals had transmitted (drug-naive group) and 
      acquired (treated group) resistance mutations, respectively. Six transmitted 
      drug-resistant mutations were found, including two mutations (L33F and L76V) in 
      the protease region and four (K70N/E and V179D/E) in the RT region. Only L76V was 
      a major mutation, and K70N/E and V179D/E are known to cause low-level resistance 
      to RT inhibitors. All 13 treated participants who had major drug resistance 
      mutations demonstrated intermediate to high resistance to efavirenz and 
      nevirapine, and six had a treatment duration of less than three months. No major 
      mutations to RT inhibitors were found, implying that the epidemic of transmitted 
      resistance mutations was not significant in this area. Our results suggest that 
      more frequent virus load and drug resistance mutation tests should be conducted 
      for individuals receiving antiretroviral treatment, especially for newly treated 
      patients. Our research provides insights into the occurrence of HIV-1 drug 
      resistance in Suzhou and will help to optimize the treatment strategy for this 
      population.
FAU - Li, Tingting
AU  - Li T
AD  - Research Group of HIV-1 Molecular Epidemiology and Virology, The State Key 
      Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, 
      Wuhan, 430071, China.
AD  - University of Chinese Academy of Sciences, Beijing, 100000, China.
FAU - Qian, Feng
AU  - Qian F
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Yuan, Ting
AU  - Yuan T
AD  - Research Group of HIV-1 Molecular Epidemiology and Virology, The State Key 
      Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, 
      Wuhan, 430071, China.
FAU - Xu, Weilu
AU  - Xu W
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Zhu, Li
AU  - Zhu L
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Huang, Jinlong
AU  - Huang J
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Wang, Haiyan
AU  - Wang H
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Zhu, Yueping
AU  - Zhu Y
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Wang, Yinling
AU  - Wang Y
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Li, Xiaohong
AU  - Li X
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Gu, Saihong
AU  - Gu S
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Tan, Zhuqing
AU  - Tan Z
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Chen, Hui
AU  - Chen H
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Luo, Xiangrong
AU  - Luo X
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Zhu, Wei
AU  - Zhu W
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Lu, Wenjuan
AU  - Lu W
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Xu, Ping
AU  - Xu P
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Li, Ming
AU  - Li M
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China.
FAU - Chen, Yuying
AU  - Chen Y
AD  - Research Group of HIV-1 Molecular Epidemiology and Virology, The State Key 
      Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, 
      Wuhan, 430071, China.
AD  - University of Chinese Academy of Sciences, Beijing, 100000, China.
FAU - Gao, Yong
AU  - Gao Y
AD  - Department of Microbiology and Immunology, Schulich School of Medicine & 
      Dentistry, University of Western Ontario, London, N6A 5C1, Canada.
FAU - Yang, Rongge
AU  - Yang R
AD  - Research Group of HIV-1 Molecular Epidemiology and Virology, The State Key 
      Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, 
      Wuhan, 430071, China.
FAU - Zhu, Chuanwu
AU  - Zhu C
AUID- ORCID: 0000-0002-9113-2046
AD  - Division of HIV-1/AIDS, the Fifth People's Hospital of Suzhou, Suzhou, 215000, 
      China. zhuchw@126.com.
FAU - Sun, Binlian
AU  - Sun B
AUID- ORCID: 0000-0002-3060-9867
AD  - Research Group of HIV-1 Molecular Epidemiology and Virology, The State Key 
      Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, 
      Wuhan, 430071, China. sunbl@wh.iov.cn.
LA  - eng
PT  - Journal Article
DEP - 20170807
PL  - Netherlands
TA  - Virol Sin
JT  - Virologica Sinica
JID - 101514185
RN  - 0 (Reverse Transcriptase Inhibitors)
SB  - IM
MH  - Adult
MH  - China
MH  - Drug Resistance, Viral/*genetics
MH  - Female
MH  - Genotype
MH  - HIV Infections/*drug therapy/genetics
MH  - HIV-1/drug effects/genetics/*pathogenicity
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Phylogeny
MH  - Polymerase Chain Reaction
MH  - Reverse Transcriptase Inhibitors/*therapeutic use
PMC - PMC6598913
OTO - NOTNLM
OT  - China
OT  - HIV-1
OT  - drug resistance mutation
OT  - first-line regimen
COIS- The authors declare that there is no conflict of interest. The study was approved 
      by the Ethics Committees of the Fifth People's Hospital of Suzhou and Wuhan 
      Institute of Virology. Informed consent was obtained from all participants in 
      this study.
EDAT- 2017/08/11 06:00
MHDA- 2018/03/13 06:00
PMCR- 2018/08/07
CRDT- 2017/08/11 06:00
PHST- 2017/04/19 00:00 [received]
PHST- 2017/07/05 00:00 [accepted]
PHST- 2017/08/11 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
PHST- 2017/08/11 06:00 [entrez]
PHST- 2018/08/07 00:00 [pmc-release]
AID - 10.1007/s12250-017-4002-y [pii]
AID - 4002 [pii]
AID - 10.1007/s12250-017-4002-y [doi]
PST - ppublish
SO  - Virol Sin. 2017 Aug;32(4):271-279. doi: 10.1007/s12250-017-4002-y. Epub 2017 Aug 
      7.